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1. Introduction 
The application of drugs through the eardrum and into the middle ear to treat various 
otologic disorders, such as Meniere’s disease and sudden sensorineural hearing loss has 
recently gained widespread popularity. The intratympanic treatment modality can provide 
also a chemoprotection strategy for exposure to noise (1) cisplatin (2), and aminoglycosides 
(3). 
Inflammatory processes may play a role in the etiology of various inner ear pathologies of 
which the pathogenesis is poorly understood. Intratymapanic corticosteroid may be a 
promising therapy for several ear disorders.  
Neurosensorial hearing loss therapy to date has consisted mostly of the systemic 
administration of steroids and has been limited by their side effects and low therapeutic 
concentrations within the fluids and tissues of the inner ear. It has been shown in animals 
and humans that systemically applied glucocorticoids reach only low drug concentrations in 
the perilymph. The local application of drugs to treat inner ear diseases is expected to 
provide advantages as compared with systemic treatments, namely: 1) bypassing the blood-
labyrinthine barrier, 2) resulting in higher concentrations in the inner ear fluids 3) avoiding 
major unwanted effects of systemically administered medications. 
Despite some successes, the local medical treatment of inner ear conditions, is often 
frustrating to patients and physicians. We review the status of the intratympanic 
corticosteroids treatment. 
2. History  
The delivery of medications to the inner ear through the transtympanic route dates back to 
1935, when Barany (4) used intratympanic lidocaine for treatment of tinnitus. Since then, 
other molecules have been used and the indications have expanded. In 1948, streptomycin 
was used to treat patients with unilateral Meniere’s disease specifically on the basis of its 
vestibulotoxic effects (5). It was Harold Schuknecht who proposed the use of streptomycin 
as an alternative to surgical unilateral labyrinthine ablation (6). Francis Bauer, in 1969 and 
1971 reported on the treatment of “Glue Ear” by using intratympanic urea (7). Another 
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interesting application of intratympanic medication was reported by Bryan in 1973, when he 
described the use of intratympanic steroids in a patient with facial paralysis (8). Itoh (9), in 
1991, used steroids for Meniere’s disease. Silverstein (10) in 1996, used steroids for 
Sensorineural Hearing Loss. 
3. Anatomy 
The cochlea can be thought of as a long coiled tube looking much like a snail shell (11). It is 
composed of three compartments. The middle compartment is the scala media, which is 
filled with endolymph. The lower and upper fluid compartments respectively are the scala 
tympani and scala vestibuli, both of which are filled with perilymph. These two 
compartments communicate with each other at the apex of the cochlea through the 
helicotrema. The round window is a membranous opening in the bone within the scala 
tympani. It sits at the base of the scala tympani and is very compliant, capable of bulging 
into the middle ear. It separates perilymph from the middle ear space. The oval window, in 
the scala vestibuli, contains the footplate of the stapes, one of the middle ear bones, that 
transmits acoustic vibrations from eardrum to the inner ear. 
4. Physiology 
Most of the structures of the cochlea are protected from the systemic circulation by the 
presence of a blood-cochlear barrier (or blood-labyrinthine barrier), similar to the blood-
brain barrier. There is exchange between the different compartments of the inner ear: 
between tympanic perilymph and vestibular perilymph and between endolymph and 
perilymph. But also between the inner ear fluids and cerebrospinal fluid and between the 
inner ear fluid and plasma (12) (13). Exchanges between endolymph and plasma are 
through the stria vascularis and between perilymph and plasma through the capillaries 
perilymphatic. At this level makes a pass filtering products: blood-labyrinthine barrier 
(13). 
This blood–inner ear barrier consist of tight junctions and other mechanisms that limit 
access of molecules to inner ear targets. In fact the endothelial cells are connected with tight 
junctions and without fenestrations (14). This network of tightly coupled endothelial cells is 
the dominant component of the blood-cochlear barrier which make this solid barrier 
impermeable to macromolecules.  In addition to this physical barrier, there is a chemical 
barrier between blood and endolymph/perilymph wich has a selectivity to electrolytes and 
water-soluble molecules  (15).  
In the fluid of the inner ear, there are other obstacles to the spread of drugs administered 
systemically: Because the scala media has a relatively high positive charge due to the 
endocochlear potential, the charge the drug carries will be a significant factor in its ability to 
enter the scala media, with positively charged drugs at a disadvantage (13).  
The relatively high protein content of perilymph will tend to bind drugs (16). Protein 
interactions with drugs are as important in the perilymph as in blood. Albumin levels are 
high and can bind acidic drugs, and acid glycoproteins can bind basic drugs (16). Partition 
coefficients of drugs with these proteins will determine free concentration of the drug. The 
free fraction of the drug binds to the sensory cells and exerts its effect (13). 
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The cochlea is surrounded by the petrous bone. It was shown that there is a direct exchange 
between the extracellular space of the petrous bone and perilymph through the lacuna 
canaliculi which are canals or holes in the bone in free communication with the scala 
tympani (17). 
5. Pharmacokinetics and pharmacodynamics 
Treatment given by intratympanic will diffuse in liquid of the inner ear. There are 3 practical 
entry points: 1) through round window membrane RWM (at the base of the cochlea on the 
scala tympani side), 2) through or near the oval window (at the base of the cochlea on the 
scala vestibuli side), 3) through the bone of the cochlea via application in the middle ear. 
This infusion is mainly through the round window.  
The RWM has three layers (18): an outer epithelial layer on the middle ear side, a middle 
fibrous layer, and another epithelial layer facing the inner ear. The outer epithelial layer 
contains some microvilli and abundant mitochondria, suggesting that it may be able to 
absorb substances and carry out metabolic activities. The inner epithelial layer has areas of 
discontinuous basement membrane that may provide space for substances to traverse the 
membrane. 
Plontke (19), and colleagues have extensively modeled the distribution of drugs applied at 
the RWM. They suggest that in addition to diffusion along the length of the cochlea, 
diffusion through the tissue of the cochlea from one scala to another must be considered as 
well. 
Some factors facilitate the passage of molecules through the round window membrane: low 
molecular weight, water-soluble nature, the ionic charge, histamine, prostaglandins, 
leukotrienes, endotoxin of E. coli, Staphylococcus exotoxins (20). The contact time with the 
round window membrane has the most important effect. Wang (21) demonstrates that the 
inner ear pharmacokinetic profile of steroids administered intratympanically is dependent 
upon the nature of the vehicle as well as the physicochemical properties of the steroid drug 
itself. In fact the degree of aqueous solubility of the drug has a major impact on its residence 
time and exposure in the inner ear (21). 
Glucocorticoid receptors have been identified in the inner ear and are more abundant in the 
cochlea (22). The presence of glucocorticoid receptors in the inner ear provides a cellular 
means by which circulating glucocorticoids can directly affect the inner ear physiology. 
Corticosteroids have been used extensively for inner ear disease because of their anti-
inflammatory effects but also affect the vascularity of the inner ear. Corticosteroids have 
many effects : they prevent a decrease in cochlear blood flow, reduce degeneration of the 
stria vascularis  and have an antioxidant effect (23). 
6. Choice of drug 
Two corticosteroids are used by the majority of the researchers: dexamethasone and 
methylprednisolone. The concentration is varied between 4 mg/ ml and 25 mg/ml for 
dexamethasone and between 32 mg/ ml and 62,5 mg/ml for methylprednisolone. 
Parnes in pharmacokinetic animal study compared intracochlear levels of three 
glucocortiocoids: dexamethasone (Dexa), methylprednisolone (MP), and hydrocortisone 
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(24). When correcting for the lower Dexa concentration (4 mg/mL) compared to MP (40 
mg/mL) in their study and for the higher potency, dexamethasone is expected to reach 
higher effective levels in perilymph after application to the round window membrane. In 
addition, contrary to Dexa, MP solution is not stable but hydrolyzed after some days in the 
pump cartridge (19) (25). 
7. Intratympanic delivery methods 
There is no standard protocol for IT corticosteroid injections; the frequency of injections, 
concentration and type of corticosteroid. Method of injection is determined by the 
individual surgeon.  
Multiple intratympanic delivery methods are descripted:        
Syringe delivery is a simple method. However, direct injections do not allow for prolonged 
delivery. We can anesthetize the tympanic membrane with 10 percent Xylocaine. A drop of 
phenol on the ear drum is one method. Another is a topical anesthetic such as "Emla" cream. 
The drug is injected, left in the middle ear for 30 minutes.  
The myringotomy is placed in the most superior and anterior location to allow maximal 
filling of the middle ear space with the corticosteroid solution while the patient is supine. 
Placement of the tube eliminates the need for a new myringotomy for each subsequent 
injection. For injection, we use a 25-gauge spinal needle attached to a 1-mL tuberculin-type 
syringe. To equalize pressure, two needle punctures were made in the anterior superior 
quadrant of the tympanic membrane, the first for injection and the second (superior) for air 
escap. The initial injection was followed by a second injection about 15 minutes later for a 
total volume of approximately 0.5 mL. The patient remained supine for 30 to 40 minutes, 
with the head turned to the side and the injected ear upright, and was instructed to swallow 
as little as possible to help maintain the fluid in the middle ear space for longer duration. 
Microwick is the polyvinyl acetate wick (1 mm diameter by 9 mm length). It absorbs 
medication and transports it directly to the RWM. It’s placed through a tube, at the round 
window niche. It allows instillation by the patient himself at home. The MicroWick should 
be removed or replaced after 4 weeks of treatment to prevent it from becoming adherent to 
the mucosa of the round window  (26). 
Microcatheter is composed of two tubes: one for injection and the other for the return of 
excess liquid. It ends with a bulge that is placed at the round window niche under general 
anesthesia. Some researchers propose to link the catheter to a pump. This would allow 
continuous irrigation and delivery of the product constantly at the round window. 
8. Indications 
Corticosteroids are indicated in several types of sensorineural affects. Indications are : 
sudden deafness, autoimmune Deafness, Deafness and Dizziness related to Meniere's 
disease and Tinnitus.  
They are also available for otoprotection against physical and chemical aggressions of the 
inner ear. It seems that corticosteroids will respond to inner ear hair cells and nerve cells. 
They may prevent, limit and recover the damage caused by noise trauma (27).  They may be 
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given in anticipation of ototoxicity that could be associated with systemic aminoglycoside 
antibiotic or cisplatinum and other chemotherapeutic agents. They can also be used after 
injuries (28). 
9. Results 
Intratympanic corticosteroids for sudden hearing loss and Meniere’s disease has been the 
subject of retrospective, uncontrolled studies and a few controlled studies with small 
numbers of subjects. Hamid in 2001 with a single injection of high concentration of 
Dexamethasone (24mg/ml) for patients with Meniere’s disease, was able to get control of 
vertigo in 90% of cases with an improvement of hearing threshold, the percentage of 
discrimination and sensation of fullness (29) (26). In his study, 90% of patients had vertigo 
control, 90% had improved speech discrimination, and 90% had decreased aural pressure. 
Garduno (30), compared intra tympanic Dexamethasone versus placebo in Meniere disease. 
He obtained full control of vertigo in 82% of cases against 57% with placebo with significant 
differences. He also noted a reduction of tinnitus in 48% of cases and hearing improvement 
in 35% of cases. 
In sudden deafness, Ahn (31) compared two groups: systemic corticosteroids alone versus 
intratympanic corticosteroids associated with systemic treatment. He found no significant 
difference in overall response, but noted a significant improvement on the low frequencies 
in intratympanic treatment group. HONG (32) compared intratympanic corticosteroids 
alone versus systemic corticosteroids alone also found no difference, but noted a significant 
improvement over the low frequencies. Alatas (33) concluded that intratympanic 
dexamethasone is an effective therapy for low frequency hearing loss. Hunchaisri (34) 
concluded that it may have benefits for patients with sudden sensorineural hearing loss who 
failed systemic steroid therapy. 
In diabetic patients with sudden sensorineural hearing loss, intratympanic corticoid 
injection is as effective as systemic steroid treatment and it can avoid undesirable side effects 
(35). Han studied three groups of diabetics and compared prednisolone administered by 
oral, intravenous and intra tympanic Dexamethasone. He noted a better outcome with 
intratympanic treatment without significant difference. However, systemic treatment was 
discontinued in 6 patients due to problems of hyperglycemia.  This disadvantage is not 
observed with the intratympanic treatment. 
Many studies concluded that using the continuous intratympanic dexamethasone by 
MicroWick is effective, safe and efficient for treatment of sudden idiopathic sensorineural 
hearing loss (26) (19). 
There is an increasing number of series evaluating intratympanic (IT) steroids as first line or 
salvage therapy in ISSHL with some studies presenting control groups and randomized 
controlled trials (Table 1). 
The effect of intratympanic corticosteroids on tinnitus is difficult to assess due to limited 
work. Shulman (37) treated tinnitus with intratympanic dexamethasone and obtained 
control of tinnitus in 50% cases (for 1 year and over). 
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Author Type of study Steroid used Protocol Results 
Gianoli 
(48) 
prospective 
 
salvage 
treatment 
Steroids through 
a ventilation tube
4 separate 
occasions over 
the course of 10 
to 14 days 
Hearing 
improvement in 44% 
Xenellis 
(49) 
Randomized 
controlled study 
Methylprednisolone salvage 
treatment 
40 mg/mL 4 
times within a 
15-day period 
 
Significant 
improvement  
Haynes 
(36) 
retrospective Dexamethasone 24 mg/mL 27.5% showed 
improvement (≥20dB) 
Ahn (31) controlled study Dexamethasone 0.3 mL on days 1, 
3, and 5 
Total recovery rate  
was 73.3% and 70.0% 
in the control group 
better hearing 
improvement at 250 
Hz than the control 
group 
Hong 
(50) 
Randomized 
controlled study 
Dexamethosone Primary 
treatment 
5mg/ml once a 
day for eight 
days 
hearing recovery rate 
compared with 
patients treated with 
oral steroids 
improvement at low 
frequencies 
Han (35) Prospective, 
nonrandomized 
multicenter clinical 
trial 
Dexamethasone SNHL with 
diabetes 
four times within 
a two-week 
period 
no significant 
difference with 
systemic treatment 
no patients who 
failed to control their 
blood sugar level 
Lee (51) retrospective Dexamethasone salvage 
treatment 
5 mg/mL, six 
injections over 2 
weeks 
significant 
improvement for 
severe SNHL 
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Author Type of study Steroid used Protocol Results 
Kara 
(52) 
Prospective control Dexamethasone 5 intratympanic 
injections with 
the dose of 4 
mg/ml, 
Intratympanic 
steroids gave better 
hearing results than 
systemic steroids 
with no systemic side 
effects 
Plontke 
(19) 
Randomized, 
double-blind, 
placebo controlled 
multicenter trial. 
 
Dexamethasone 4 mg/ml 
continuously 
applied for 14 
days 
better hearing 
improvement in the 
treatment group 
absence of serious 
adverse events 
Table 1. Review of Literature on Intratympanic steroid Therapy for sudden neurosensorial 
hearing loss 
The effectiveness of steroids in reducing noise induced hearing loss has been inconclusive 
(13). Many types of steroids, antioxidants and growth factors have been studied to protect 
the ear from trauma or to minimize or reverse damage (38) (39). Some researchers have used 
antioxidants such as D-methionine and N-acetylcysteine to prevent noise induced hearing 
loss (40). A variety of growth factors and peptides, are being introduced to combat the 
effects of Noise induced hearing loss :  Insulin-like growth factor-1 (IGF-1), neurotrophic 
factor-3 (NT-3) , AM-111 and D-JNKI-1 peptides (41) (42) (40). 
Steroids have also been tested for their otoprotective attributes during antibiotic treatment. 
The intracochlear infusion of dexamethasone before and after kanamycin delivery protected 
hearing (43). Hill (44) concluded that IT dexamethasone may be a safe, simple and effective 
intervention that minimizes cisplatin ototoxicity without interfering with the 
chemotherapeutic actions of cisplatin. 
A sudden or progressive hearing loss can occur during radiation treatment of head and neck 
tumors (45). Patients are commonly given steroids to reduce inflammation, but their local 
delivery would reduce the side effects associated with systemic steroid treatment (13). 
Inflammation often results from inner ear surgical trauma, as well (46). 
10. Complications 
Complications of intratympanic injections of corticosteroids are uncommon and banal (19). 
Those most often reported in the literature are: 1) some individuals experience intense pain 
during injection, 2) vertigo and tinnitus, 3) Other complications are rare and include acute 
otitis media and mastoiditis. 
Patients who undergone trans-tympanic aerator to avoid multiple injections or to put in the 
microwick have an increasing risk of persistent eardrum perforation (47). In fact, 20% of 
these patients had non healing perforations that needed repair using a fat graft (26). 
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11. Conclusion 
The intratympanic treatment has several advantages. It is an effective procedure for the 
control of cochleovestibular disorders such as sudden deafness and Ménière's disease. Up 
till now, there is no consensus on the IT protocol. Future studies will define the best 
prtocole. The perspective is the development of the gene therapy and the intracochlear 
treatment. 
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